Related Experiment Video

Updated: Apr 25, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.1K

PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy

Gloria Irene Manfredi1, Alessandra Dicitore, Germano Gaudenzi

  • 1Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

Endocrine
|August 14, 2014
PubMed

Insights

The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is crucial in neuroendocrine tumor progression. Targeting this pathway offers potential new therapies for advanced medullary thyroid cancer (MTC).

Area of Science:

  • Oncology
  • Molecular Biology
  • Signaling Pathways

Background:

  • The PI3K/Akt/mTOR pathway regulates critical cellular processes like proliferation and apoptosis.
  • This pathway is increasingly implicated in the pathogenesis and progression of neuroendocrine tumors.
  • Medullary thyroid cancer (MTC) is a neuroendocrine tumor associated with RET proto-oncogene mutations.

Purpose of the Study:

  • To review the role of the PI3K/Akt/mTOR pathway in MTC development and progression.
  • To explore novel therapeutic strategies targeting this pathway for advanced MTC.

Main Methods:

  • Literature review of studies on PI3K/Akt/mTOR signaling in MTC.
  • Analysis of the connection between RET mutations and PI3K/Akt/mTOR pathway deregulation.
  • Examination of potential therapeutic inhibitors targeting the pathway.

Main Results:

  • The PI3K/Akt/mTOR pathway is dysregulated in MTC, contributing to tumorigenesis.
  • RET proto-oncogene mutations can lead to PI3K/Akt/mTOR pathway activation.
  • Targeting the PI3K/Akt/mTOR pathway shows promise for MTC treatment.

Conclusions:

  • The PI3K/Akt/mTOR pathway is a key player in MTC pathogenesis.
  • Inhibiting this pathway represents a viable therapeutic avenue for advanced MTC.
  • Further research into dual-targeting strategies may enhance treatment efficacy.

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.2K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K